AzTrials
AzTrials

Pain, PostoperativePhase 4NCT06146491

A COMPARISON OF TRANSDERMAL DICLOFENAC AND ORAL COMBINATION OF PARACETAMOL AND IBUPROFEN IN POSTOPERATIVE PAIN MANAGEMENT FOLLOWING SURGICAL EXTRACTION OF MANDIBULAR THIRD MOLAR- A RANDOMISD CONTROLLED TRIALS.

A Phase 4 study testing Oral tablet and transdermal patch in people with Pain, Postoperative, run by B.P. Koirala Institute of Health Sciences at 1 site in Nepal.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

This is comparative interventional study, will be conducted in patient indicated for surgical extraction of mandibular third molar at the Department of Oral and Maxillofacial surgery, College of Dental Surgery, BPKIHS, Nepal. Verbal and written will be taken . Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Pain, Postoperative
What is being tested?
Oral tablet and transdermal patch
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
108 participants
Where
1 siteNepal
Study dates
10 Aug 2023to 15 Jan 2024
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Inclusion Criteria:Patients of ASA I and ASA II, who are consenting for the study.

Patient indicated for surgical extraction of mandibular third molar -

Exclusion Criteria:Hypersensitivity to local anesthetic agent Patient who are physically and mentally healthy Patient not consenting to participate in the study Pregnant females in their first and third trimester of pregnancy. Patients allergic to diclofenac and oral combination of Paracetamol and Ibuprofen.

Patient taking any analgesic at the time of surgery. Patient on anticoagulant therapy. Patient under Corticosteroids therapy. Patient needing pre-operative antibiotics prophylaxis Patient having peptic ulcerative disease. Patient having acute localized infection like pericoronitis.

-

Trial locations and contacts

1 site in 1 country.

Nepal1 site, 1 recruiting
  • Niroj khanal

    Dharān, Koshi, 56700

    Niroj KHANAL, Master, +9779822980152, nkkhanal99@gmail.com

    Rojeena Adhikari, bachlor, +9779845692402, rojeeadh@gmail.com

    Recruiting

Other trials in Nepal

About this study

Official title: A COMPARISON OF ANALGESIC EFFICACY OF TRANSDERMAL DICLOFENAC AND ORAL COMBINATION OF PARACETAMOL AND IBUPROFEN IN POSTOPERATIVE PAIN MANAGEMENT FOLLOWING SURGICAL EXTRACTION OF MANDIBULAR THIRD MOLAR

This is comparative interventional study, will be conducted in patient indicated for surgical extraction of mandibular third molar at the Department of Oral and Maxillofacial surgery, College of Dental Surgery, BPKIHS, Nepal. Verbal and written will be taken . Participants meeting inclusion criteria will be included in the study and will be divided in to two groups, group A (Oral combination of paracetamol-500mg and ibuprofen -400mg) and group B ( Transdermal diclofenac patch-200mg) using computer generated randamization. Extraction will be carried out using standard protocol. Aformention drugs will given to participants accordingly for management of post operative pain.Tramadol will be given to each patient as rescue analgesics and allowed to have if pain score exceeds 7.post operative instruction will be given carefully. Rescue phone number will be provided in case of emergency. Telephonic interview will be performed at 12, 24 and 72 hours post operatively and pain score using numeric rating scale will be recorded.Any adverse effects of drugs will be recorded. The data collected will be entered in Microsoft excel sheet. It will then be transferred into SPSS (Statistical Package for Social Sciences) for statistical analysis.

Read the detailed description

Introduction:unpleasant sensory and emotional experience associated with, or resembling that associated with, actual or potential tissue damage" is the new definition of pain as per IASP 2020. Pain is one of the most commonly experienced symptoms in oral and maxillofacial surgery and as such is a major concern to the surgeon. One of the most important aspects of the practice of dentistry is the control or elimination of pain. Pain is one of the most common post-operative complication following surgical removal of mandibular third molar extraction. To ameliorate the pain we commonly prescribe NSAIDS like oral Paracetamol ,ibuprofen, oral diclofenac sodium etc. Non steroidal anti inflammatory drugs work well to relieve mild to moderate intense postoperative pain. Their mechanism of action depends on whether they inhibit cyclooxygenase-1 (COX-1), cyclooxygenase-2 (COX-2), or both, which are responsible for the synthesis of different prostaglandins found in pathological situations (COX-2 is more expressed in inflammatory conditions). NSAIDS can be administered in a variety of routes, including oral, par-enteral, inhalation as well as trans dermal. Through Oral route is the most common for the drugs delivery. Oral route carries the risk of first pass metabolism and loss of substantial quantities of the drug before it is absorbed systemically. Par-enteral administration of drugs can be extremely painful and sudden increase in drug concentration in the plasma could lead to certain adverse effects. Trans dermal patches offer several advantages over the oral route such as bypassing first pass metabolism, slow controlled absorption, constant plasma concentration which is maintained for a longer duration, no patient dependence for drug doses, no gastric discomfort, and flexibility of terminating the drug administration by simply removing the patch from the skin.

Rarionale of the study:The three characteristics of the pain that occurs after routine tooth extraction:(1) The Pain is usually not severe and can be managed in most patients with over-the-counter analgesics, (2) the peak pain experience occurs about 12 hours after the extraction and diminishes rapidly after that, and (3) significant pain from extraction rarely persists longer than 2 days after surgery. Non steroidal anti inflammatory drugs (ibuprofen, paracetamol etc )has the ability to reduce both pain and inflammation as a result they are the ideal analgesic agents for the control of pain in the events of surgical removal of mandibular third molar. NASIDS drugs can be administered in a variety of routes, including oral, par enteral, inhalation as well as trans dermal. Oral route is the most common for the drugs delivery. Oral NSAID may causes nephrotoxicity and hepatotoxicity'.Oral route carries the risk of first pass metabolism and loss of substantial quantities of the drug before it is absorbed systemically. Par enteral administration of drugs can be extremely painful and sudden increase in drug concentration in the plasma could lead to certain adverse effects. Trans dermal patches offer several advantages over the oral route such as bypassing first pass metabolism, slow controlled absorption, constant plasma concentration which is maintained for a longer duration, no patient dependence for drug doses, no gastric discomfort, and flexibility of terminating the drug administration by simply removing the patch from the skin. Plasma concentration of a topically applied NSAID was found to reach only a fractional level (less than 5%) of that achieved after oral administration.[8] A lower plasma drug concentration limits the systemic side effects and has an auxiliary advantage of improved action at the site of inflammation. Trans dermal delivery is associated with a lesser incidence of GI adverse effects and is particularly useful in patients unable to tolerate an oral route. However, no such reduction was documented with occurrences of heart and renal failure, which have been connected to oral NSAID usage.This study attempts to compare effectiveness of trans dermal diclofenac and oral paracetamol + ibuprofen in postoperative pain management following surgical extraction of mandibular third molar.

Sampling Method: purposive sampling

Expected sample size: study will be carried in 108 people visiting in oral and maxillofacial department, BPKIHS for surgical extraction of mandibular third molar.

Procedure: All consecutive participants who met the inclusion criteria will allocated to the oral paracetamol-500mg and ibuprofen-400mg ( group A) or trans dermal diclofenac-200mg ( group B) by computer generated random number .The surgical procedure will performed by same surgeon under same environmen using standard surgical protocol. Local anaesthesia will be provided by technique of regional blockade of the inferior and lingual alveolar nerves, with supplementary buccal nerve infiltration. A careful and slow injection of the solution will conducted after negative aspiration, with 2% lidocaine and 1:200,000 epinephrine. The incision will be given as per wards incision technique. Howarth's periosteal elevator will be used to reflect a full thickness mucoperiosteal flap and will be retracted with Austins re tractor. Buccal and distal bone removal will be done with a round bur on a straight hand piece under constant irrigation with 0.9% sterile normal saline solution and guttering done a little beyond bifurcation. After the tooth delivery socket will be inspected, irrigated and flap sutured with a 3-0 (vicryl). One suture will place just distal to the lower second molar and another on the distal aspect of the extraction socket. Duration of surgical procedure will be recorded. The post extraction instruction will be given carefully. Following removal of the impacted mandibular third molar, the oral group will given 500mg paracetamol and 400mgtablet thrice daily 30 minute while the trans dermal diclofenac group will be given diclofenac patch 200mg immediately after surgery daily for three consecutive days. Diclofenac trans dermal patch will be placed on right arm. Information on regimen and application of oral and trans dermal diclofenac was obtained from previous study[3] Patients were instructed to apply 0.12% chlorhexidine digluconate aqueous solution to control dental plaque from the second day, every 12 hours for 7 days. All patients will be given amoxicillin trihydrate. 500mg 8 hourly or erythromycin250mg 6 hourly for those who were allergic to penicillin, metronidazole 400mg 8 hourly, both for five days .pentaprazole 40 mg daily for 5 days will be given. These drugs were commenced immediately after surgery. Tramadol tablets 50mg every 8 hours will be prescribed as rescue analgesic and patients will be instructed to take it only if pain score greater than 7. consent will be taken from All subjects verbal and written patients will be taken , participaints will instructed to present to the emergency department in the event of delayed post extraction complications like uncontrolled bleeding and unbearable pain. The patients will be evaluated by the same observer. Pain will be evaluated using a Numeric Rating Scale (NRS) by telephonic interview. The assessment of pain will be done at three time points: 12, 24 and 72 hours post-operatively. The number of paracetamol tablets taken after surgery by the patients will be recorded after 3 days post -operatively.

Statistical methods proposed:

Descriptive Analysis:

Descriptive statistics, such as mean, standard deviation, median, and percentage will be applied.

Inferential statistics:

Student's t test or Mann Whitney u test will be applied to compare the observation between the two groups.

Likewise chi square test will be used to compare the proportions between two groups.

Being tested
Oral tablet and transdermal patch
Medical subject headings
Pain, Postoperative

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Oral tablet and transdermal patchDrug

    oral combination of paracetamol -500mg and ibuprofen - 400mg will be given to group A and transdermal diclofenac patch - 200 mg will be given to group B.

Study groups in NCT06146491
Study groupRoleWhat they receive
DrugsActive comparatororal combination of paracetamol (500mg) - ibuprofen (400mg) will be given to group A. they are provided in tablet and prescribed at 8 hourly for three days
Receives: Drug: Oral tablet and transdermal patch
DrugActive comparatorTransdermal diclofenac patch - 200mg for group B. Patch is applied on right hand in deltoid region , and ask the patient to change patch every 24 hourly.
Receives: Drug: Oral tablet and transdermal patch

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. To compare the analgesic effectiveness of diclofenac trans dermal patch (200mg) and oral combination of paracetamol (500mg) and ibuprofen (400mg) following surgical removal of mandibular third molar.

    Measured: 2 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Nov 2023
  2. Study start10 Aug 2023
  3. Primary completion15 Jan 2024 (estimated)
  4. Study completion15 Jan 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
108 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06146491
Sponsor's protocol ID
IRC/2223/022
Status last verified
Nov 2023
First submitted
19 Nov 2023
Last updated
24 Nov 2023
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Oral tablet and transdermal patch in people with Pain, Postoperative, run by B.P. Koirala Institute of Health Sciences at 1 site in Nepal.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 24 Nov 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Nepal. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

To compare the analgesic effectiveness of diclofenac trans dermal patch (200mg) and oral combination of paracetamol (500mg) and ibuprofen (400mg) following surgical removal of mandibular third molar. (time frame: 2 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Nov 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in